Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: 28jaczar01, 14 May 2021 22:29
Last post: 28jaczar01, 16 Jun 2021 09:50
In line with my previously stated expectations about big pharma continuing to do takeovers of existing established diagnostics companies. I have just seen the announcement about the BBI takeover by Novo……Wonder when others (NCYT, GDR, ABDX, ODX, etc) could follow….
Good luck to all on this board with your impending takeover .
I’m not crossramping 28jazcar but as you mentioned NCYT which I am invested in and have been for the last 15 months I have seen many similarities and agree with your sentiments on small to mid cap diagnostic companies been snapped up by the big boys .
Yep, I don’t think it was a coincidence Antha......
One of my investing methods is to look out for such signs that are outside of the normal pattern of trading.....
I was planning on increasing my IDH holding today having seen those delayed 13th May trades over the weekend but alas the RNS has put paid to that.....anyway it’s still been a nice earner of 70% profit for a 6 month hold.
Best of luck with how you re-invest your profits. Personally I am taking a look at EVG which has some great IP and is cashed up but seems to have been forgotten by the market for the time being.
28ja, those mega buys and the timing would suggest to me there was a bit of insider trading going on, too coincidental.
Good call 28J!
Congrats to all holders!
Started: oldbutnowisa, 17 May 2021 09:51
Last post: Rajbury, 3 Jun 2021 21:50
by whom?
Another offer by who?
IDH was always a well run company with great assets but not that good for short term traders (sorry draft), my strategy was to hold long term with maybe a T/O at some point, honestly didn't think it would happen so quickly.
Best not to sell just in case a bidding war starts, well done all.
Indeed.....Certainly no harm in waiting for it to play out.
I would not be surprised by a higher offer and it go contested.
Started: 28jaczar01, 17 May 2021 09:38
Last post: 28jaczar01, 17 May 2021 09:38
Diagnostics company buyouts - new trend ?
The news here this morning has come sooner than I had envisaged and allows me to bank a nice profit...... -;)
However I think there is a bigger picture story potentially going on here whereby the previous sleepy town of the diagnostics world has really been woken up for the future by the covid pandemic.
Going forwards I can foresee that many of the large pharma companies will be looking to enhance their diagnostics credentials / capabilities. One of the fast-track ways to do this is to look to buy-out small to medium size existing diagnostics companies who have good IP etc, just like what has happened here with IDH.
I really see this as a wake up call for other Companies in this space such as the likes of GDR, ODX, NCYT etc......
28jaczar01/ Antha - You two were spot on with your takeover comments.
This share is a medium to long term hold and always has been, I like it because it's stable with good steady growth even during the pandemic, I agree with the previous post in that at some point IDH will probably be taken over.
Draft, That puts them in the same grouping as the majority of the diagnostics companies doesn’t it? You are quoting pretty much the 1 off exception of Novacyte (whose star has been rapidly falling in recent weeks)......
Whilst the covid story is far from over towards offering future business opportunities to IDH as mentioned in their RNS, there is plenty to like about these improved results in the last 6 months and the future growth potential. Also nice to see a cash holding sat at nearly 1/2 their mcap and so there is no chance of a placing around the corner.
I actually see IDH as a potential takeover target down the line for their IP etc, as the fallout from covid will surely be to put a new level of importance and focus on diagnostics in the eyes of the big pharmaceutical companies.
they have failed to capitalise on covid test kits when people like novacyte have made hundreds of millions from them
awful update.
I sold for a loss about 3 weeks ago.
Started: oldbutnowisa, 9 May 2021 12:06
Last post: oldbutnowisa, 9 May 2021 12:06
is anticipating better news in the finals in a month or so, but if their Covid test product is taken up then the effect on their fairly modest usual profit could be significant. It would only take that pointer to move the SP here pretty sharply upward because very small capitalisation. Could be interesting few months.
Started: 28jaczar01, 30 Apr 2021 10:03
Last post: Antha, 30 Apr 2021 13:00
Yes certainly looking good, I think the new base is 250p.
Just noticed hidden over on the Aquis exchange by those cheeky MMs, there is another delayed trade on 28th April at 112.5K which also looks to me to be a buy.......this is very interesting accumulation by someone as added together they are 0.73% of the total shares issued.....
Interesting to see 3 delayed trades showing up from 28th April for a total 100K shares done within a 1/2 hour period.....
I suspect they are all buys from the same buyer considering the SP has risen since then and this amount of shares represents several weeks of trading normally......
Let’s see where we head in the coming weeks with further IDH news etc....
I wouldn't read too much in to that, think it would only get a rns if a substantial contract was awarded which I assume none as yet have.
As I said before IDS is a very long term hold, without news it will inevitably dip below 200p again, I will be buying more then.
I reduced my holding and now this and they did not RNS this
IDS
@IDSDiagnostics
We welcomed the French Minister of Public Accounts, Olivier Dussopt to IDS Pouilly-en-Auxois site yesterday, after being one of the 35 winning companies in the health sector to be selected by the government to receive investment and further our vital work.
Started: oldbutnowisa, 20 Apr 2021 17:45
Last post: oldbutnowisa, 20 Apr 2021 17:45
....so not under the radar any longer.
Started: lsejp, 20 Apr 2021 16:09
Last post: 28jaczar01, 20 Apr 2021 17:40
Very small free float of shares with IDH so it won’t take much buying as this week progresses to keep the SP heading north to hit £3+
Actually, it rose to 230p before falling back to 190p late yesterday and then immediately going up again today, hopefully it's due to incoming news, Covid sales figures maybe.
Even with the sp rise the company is still well under valued considering their extensive IP portfolio and cash in the bank, near term it should be 300p plus.
Something fishy! It was up 23% on just one trade this morning!
more than 20% rise today - someone knows something. News tomorrow?
Started: oldbutnowisa, 20 Apr 2021 11:18
Last post: oldbutnowisa, 20 Apr 2021 11:18
...someone is sniffing around us at last.
That's the difference, this WASN'T a Covid test kit company, it only started getting in to test kits late last year and in fact in the rns it states "Revenue from this product portfolio has helped IDS deliver the strong performance seen in H2 FY21" so they are indeed making money from their Covid testing portfolio.
I disagree with all of you, this was above 260p during the main 'pandemic' and they have failed to capitalise on it
most covid companies did well like avacta, genedrive, novacyte
this covid test kit company bloody went DOWN during this mess
Started: oldbutnowisa, 6 Apr 2021 13:47
Last post: Antha, 16 Apr 2021 09:17
Nice steady growth but the important bit in the rns is..
"IDS now has a comprehensive portfolio of COVID-19 tests available - ranging across fully automated IgG and IgM antibody tests, manual ELISA tests and distribution rights for a variety of rapid antibody and antigen tests. Revenue from this product portfolio has helped IDS deliver the strong performance seen in H2 FY21.
As explained in our most recent Interim Report, the focus of health authorities is currently on antigen testing - to test for an active infection of SARS CoV-2. IDS is working with our partners to gain approval for more convenient antigen tests, which are not reliant on the unpleasant nasopharyngeal swab sample collection method, to the European market. We will be well positioned to secure a share of this market assuming approval of these products is forthcoming.
In terms of antibody testing, with the progression of the vaccine rollouts globally, public health studies into antibody levels in the population should increase to enable the success of this program to be measured. This is likely to drive additional demand for antibody testing, and because a fully automated solution such as that offered by IDS provides better accuracy than rapid tests, and better laboratory efficiency than manual ELISA based tests, IDS is well positioned to win a share of the laboratory business for these tests."
Yep normally middle of April, if the numbers are good then a short term spike to about 300p before inevitably falling back. One thing this company must improve on is a more regular news flow such as sales etc.
.... about 10 days.
Started: oldbutnowisa, 16 Apr 2021 09:08
Last post: oldbutnowisa, 16 Apr 2021 09:08
Could have been worse, but not going to set the SP on fire! At least they still have plenty of cash in the bank and, ironically, it could be a blessing in disguise that their business is not dependant on Covid going forward!
this has done the worst out of the covid test kit companies, most others have had decent spikes
theres still no proper trading update with numbers
we need real numbers, how many tests have these guys even sold so far?
So much potential here...
If each machine can do 10,000 (accurate, automated) tests per month, that's 300 per day, or maybe one/two aircraft's worth. If/when we can all start flying again, that could be one machine per flight..... or 100 machines per cruise departure?????!!
Anyway, just hoping I can get back into profit and at least the spread has narrowed.
The main points:
The Test has received the US Food and Drug Administration's ("FDA") Emergency Use Authorisation ("EUA"). As a result, IDS is now able to sell the Test to laboratories in the USA for clinical testing purposes.
The Test has been developed for identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Test exceeds the FDA`s sensitivity and specificity requirements for laboratory run serology tests. It provides 100% Positive Percent Agreement after 7 days of diagnosis by RT-PCR and 99.6% Negative Percent Agreement for pre-endemic samples.
The Test does not cross react with other strains of coronavirus, significantly reducing the risk of false positives.
All steps of the Test are automated with no manual reagent preparation required, ensuring a high daily throughput. Test results are available within 25 minutes and can be run on any of the IDS-iSYS analysers which are already installed in numerous hospitals and laboratories in the USA. Each iSYS is capable of running over 10,000 tests per month.
Tests will be available for sale at the end of April. By providing our customers with this fully automated and flexible laboratory solution, IDS has the potential to increase our testing volumes in the US market, as well as attract new customers to the IDS platform.
READ IT CAREFULLY!!!
It does talk about sales of Covid 19 tests to date, without telling us how big they have been. At this SP, there is a lot of scope for upside surprise and not much downside.
Started: Antha, 25 Mar 2021 16:09
Last post: Antha, 29 Mar 2021 11:26
All sales figures including Covid tests will be in the update released in two weeks time, that's when the sp should rise significantly.
No one interested in the RNS?
Not long now.
This is the IDS-iSYS analyzer automated test I've been waited for, they should have done it months ago but at least they have it now. What this means is that they will hopefully now sell a load more of their really expensive automated testing machines, surprised really at the low Mcap still, it will re-rate at some point.
Definitely below the radar this one.
any other covid test company we would be up 100%!
radio silence from IDH.
a trading update is needed really.
Started: draft, 23 Feb 2021 21:59
Last post: draft, 23 Feb 2021 21:59
test they make for Technogenetics to the site, i just reckon we have not sold much and now we have surplus stock of the tests possibly
Started: draft, 23 Feb 2021 21:49
Last post: draft, 23 Feb 2021 21:49
LOOK at the balls up - so we are not even selling into one of the largest markets!!!!!!!!
TGS COVID-19 IgGii is a fully automated QUANTITATIVE chemiluminescent test for identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
When effective SARS-CoV-2 vaccines becomes reality, the level of antibodies is an important indicator of a person’s immune response to the virus. Thus, the SARS-CoV-2 antibody response levels may help determine the effectiveness of vaccines and therapies.
TGS COVID-19 IgMii is a fully automated chemiluminescent test to qualitatively detect antibodies that emerge early in the course of infection.
The automated IgG and IgM tests can be used together on the IDS system, to provide the most accurate view of the patient’s immune response. A 95.8% positive sample agreement with RT-PCR after 7 days of diagnosis and 98.6% agreement with presumed negative samples when the IgM and IgG results are combined together.
ErbaLisa® COVID-19 IgGii and ErbaLisa® COVID-19 IgM ELISAii testing solutions are suitable for use on open automated ELISA systems.
iEuropean Commission (2020). Guidelines on COVID-19 in vitro diagnostic tests and their performance (published 15 April 2020). https://ec.europa.eu/info/sites/info/files/testing_kits_communication.pdf
ii Not Available in USA.
the problem is these guys appear to be reselling some chinese made tests
and then making tests for other companies that were mentioned
we don't seem to have a unique USP here anymore
I'm not happy., maybe sales will be good but i still reckon this is a bit of a balls up possibly
This could be the star of the show Monday completely under the radar odx avacta braveheart and genedrive a given but I just wonder if this dog will have its day also and im here rattling around nobody home here's hoping
this lot really have ballsed this up
Started: oldabutnowisa, 29 Jan 2021 15:00
Last post: oldabutnowisa, 29 Jan 2021 15:00
about my only holding NOT to fall!